Acute Ischemic Stroke
Conditions
Interventions
Experimental group:intravenous tirofiban plus MT therapy
Control group:MT therapy with no antiplatelet drugs (intravenous or intra-arterial) are administered
Sponsors
East Hospital, Tongji University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-80 years(inclusive); 2. Patients with acute ischemic stroke within 4.5-24 hours of onset, NIHSS score>5; 3. Patients with acute large vessel occlusion including internal carotid artery and middle cerebral artery M1 and M2, and who plan to receive arterial thrombus removal treatment; 4. Complete multi-mode CT evaluation, and meet the following conditions: penumbra> 10ml, infarct core volume 1.2; 5. Patients who plan to receive arterial thrombectomy therapy; 6. Provide the informed consent form of the patient or the patient's agent.
Exclusion criteria
Exclusion criteria: 1. Patients with a history of atrial fibrillation or atrial flutter, or a 12-lead electrocardiogram at random after admission, showing atrial flutter or atrial fibrillation; 2. Intravenous thrombolysis has been performed; 3. There is dysfunction before the onset, mRS score >= 2 points; 4. Accompanied by severe comorbidities (such as severe cardiopulmonary insufficiency, the expected survival period of advanced malignant tumors is less than 90 days); 5. CT showed low-density lesions exceeding 1/3 of the blood supply area of the middle cerebral artery; 6. Those who are allergic to tirofiban or have any contraindications to the use of tirofiban (patients with active internal bleeding, history of intracranial hemorrhage, intracranial tumors, arteriovenous malformations and intracranial aneurysms, who have previously used tirofiban) Patients with thrombocytopenia); 7. Multi-mode CT/MRI examination of the corresponding contrast agent use contraindications (such as contrast agent allergy, etc.); 8. Women during pregnancy or lactation; 9. Patients currently participating in other clinical research trials; 10. Other conditions judged by the investigator as not suitable for inclusion in the clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Composite rates of target vessel revascularization and no symptomatic intracerebral haemorrhage; | — |
Secondary
| Measure | Time frame |
|---|---|
| Recanalisation rates of the target vessel;Dichotomized mRS score/ ordinal mRS score;Symptomatic intracerebral haemorrhage;Death;The number of thrombectomy times; | — |
Countries
China
Contacts
Public ContactLi Gang
East Hospital, Tongji University School of Medicine
Outcome results
None listed